TMJ Pain and Crepitus Occur Early Whereas Dysfunction Develops Over Time in Rheumatoid Arthritis

Aims: To investigate inflammatory mediator levels in TMJ synovial fluid (SF) and blood and to investigate clinical TMJ symptoms in relation to general and TMJ symptom duration in patients with rheumatoid arthritis (RA). Methods: Examination of 80 TMJs (68 patients; median age 55 years; 85% women) included the following variables: TMJ pain at rest, maximum mouth opening, and palpation; jaw movement capacity; number of painful movements; crepitus; and degree of anterior open bite. Levels of tumor necrosis factor (TNF), TNF soluble receptor II, interleukin 1β, IL-1 receptor antagonist, IL-1 soluble receptor II, and serotonin in TMJ SF and blood; systemic disease activity; and duration of general and TMJ symptoms were assessed. General symptom duration ≤ 2 years was considered early RA. Results: TMJ symptoms predominantly developed within 5 years following general symptom onset. Logistic regression analysis showed that number of involved joints, general pain, maximum mouth opening, anterior open bite, and TNF plasma levels combined explained 46% of the distinction between early and established RA. Furthermore, TMJ pain at rest and maximum mouth opening, contralateral laterotrusion, painful movements, crepitus, and SF TNF levels combined explained 35% of the distinction. In these analyses, higher general pain and maximum mouth opening, TMJ pain on maximum mouth opening, and crepitus were associated with early RA. Conclusion: This study indicates that TMJ pain and crepitus in RA usually occur within 2 years following general symptom onset. Pain-related dysfunction and structural changes develop with time. TNF in plasma and TMJ SF are associated with this development. This makes early (clinical) recognition of pain and inflammation important, enabling early treatment to minimize later irreversible damage.

inflammatory mediators; pain; rheumatoid arthritis; synovial fluid; temporomandibular joint

1. Veale DJ, Orr C, Fearon U. Cellular and molecular perspectives in rheumatoid arthritis. Semin Immunopathol 2017;39: 343–354.

2. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol 2018;30:207–214.

3. Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7:R784–R795.

4. Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E. Diagnosis and classification of rheumatoid arthritis. J Autoimmun 2014;48–49:26–30.

5. Savtekin G, Sehirli AO. Rheumatoid arthritis in temporo-man-dibular joint: A review. Niger J Clin Pract 2018;21:1243–1246.

6. Alstergren P, Ernberg M, Kvarnström M, Kopp S. Interleukin-1beta in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility, and anterior open bite. J Oral Maxillofac Surg 1998;56:1059–1065.

7. Nordahl S, Alstergren P, Kopp S. Tumor necrosis factoralpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J Oral Maxillofac Surg 2000;58:525–530.

8. Heidari B. Rheumatoid arthritis: Early diagnosis and treatment outcomes. Caspian J Intern Med 2011;2:161–170.

9. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 6):vi28–vi36.

10. Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: A systematic literature review. J Pain Symptom Manage 2011;41:1073–1093.

11. Alstergren P, Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Determination of temporomandibular join fluid concentrations using vitamin B12 as an internal standard. Eur J Oral Sci 1995;103:214–218.

12. Alstergren P, Appelgren A, Appelgren B, Kopp S, Nordahl S, Theodorsson E. Measurement of joint aspirate dilution by a spectrophotometer capillary tube system. Scand J Clin Lab Invest 1996;56:415–420.

13. Alstergren P, Kopp S, Theodorsson E. Synovial fluid sampling from the temporomandibular joint: Sample quality criteria and levels of interleukin-1 beta and serotonin. Acta Odontol Scand 1999;57:16–22.

14. Alstergren P, Pigg M, Kopp S. Clinical diagnosis of temporo-mandibular joint arthritis. J Oral Rehabil 2018;45:269–281.

15. Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother 2017;92:615–633.

16. Hajati AK, Alstergren P, Näsström K, Bratt J, Kopp S. Endogenous glutamate in association with inflammatory and hormonal factors modulates bone tissue resorption of the tem-poromandibular joint in patients with early rheumatoid arthritis. J Oral Maxillofac Surg 2009;67:1895–1903.

17. Hajati AK, Näsström K, Alstergren P, Bratt J, Kopp S. Temporomandibular joint bone tissue resorption in patients with earlyrheumatoid arthritis can be predicted by joint crepitus and plasma glutamate level. Mediators Inflamm 2010;2010:62780.

18. Alstergren P, Kopp S. Insufficient endogenous control of tumor necrosis factor-alpha contributes to temporomandibular joint pain and tissue destruction in rheumatoid arthritis. J Rheumatol 2006;33:1734–1739.

19. Ahmed N, Petersson A, Catrina AI, Mustafa H, Alstergren P. Tumor necrosis factor mediates temporomandibular joint bone tissue resorption in rheumatoid arthritis. Acta Odontol Scand 2015;73:232–240.

20. Emery P, Bingham CO 3rd, Burmester GR, et al. Certolizumab pegol in combination with doseoptimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis 2017;76:96–104.

21. Uchiyama Y, Murakami S, Furukawa S. Temporomandibular joints in patients with rheumatoid arthritis using magnetic resonance imaging. Clin Rheumatol 2013;32:1613–1618.

22. Tegelberg A, Kopp S. Subjective symptoms from the stomato-gnathic system in individuals with rheumatoid arthritis and os-teoarthrosis. Swed Dent J 1987;11:11–22.

23. Deane KD, Holers VM. The natural history of Rheumatoid Arthritis. Clin Ther 2019;41:1256–1269.

24. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094–1108.

25. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861–1874.

26. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet 2017;389:2338–2348.

27. Kurtoglu C, Kurkcu M, Sertdemir Y, Ozbek S, Gürbüz CC. Temporomandibular disorders in patients with rheumatoid arthritis: A clinical study. Niger J Clin Pract 2016;19:715–720.

28. González-Chávez SA, Pacheco-Tena C, Campos-Torres RM, et al. Temporomandibular and odontological abnormalities in patients with rheumatoid arthritis. Reumatol Clin2020;16:262–271.